Bringing Curative Cell Therapies To Market with Kite Pharma's Cindy Perettie

What It Covers

Kite Pharma EVP Cindy Perettie details the operational, manufacturing, and commercial strategy behind scaling CAR-T cell therapies globally, covering the upcoming Anito-cel multiple myeloma launch, the Arcellx collaboration structure, next-generation pipeline development, and how Kite's manufacturing benchmarks outperform competitors across turnaround time and reliability metrics.

Key Questions Answered

• •CAR-T Manufacturing Benchmarks: Kite's in-house manufacturing delivers product in 15–17 days with 96% first-run reliability, compared to competitor turnaround times of 30–40 days and roughly 80% reliability. Companies evaluating cell therapy partnerships should treat manufacturing speed and reliability as primary patient outcome variables, not secondary operational metrics.
• •Community Access Expansion: Kite grows its U.S. authorized treatment center network by 20–25 sites annually, now approaching 180 U.S. locations from over 570 globally. Securing FACT accreditation for community practices, released at ASH, is the regulatory mechanism unlocking outpatient delivery — a prerequisite before broader geographic access becomes feasible for next-generation therapies.
• •Collaboration Structure with Arcellx: Under the Anito-cel partnership, Arcellx contributes the therapeutic construct while Kite handles global manufacturing, regulatory affairs, and ex-U.S. commercialization. Both companies co-promote in the U.S. This division — innovation from the smaller partner, scale infrastructure from the larger — is presented as a replicable model for cell therapy commercialization broadly.
• •In Vivo Cell Therapy Bet-Hedging: Kite is pursuing both integrating and non-integrating in vivo approaches simultaneously following the Interius Biotherapeutics acquisition, which brought modular vector manufacturing and strong IP. A parallel strategic collaboration with China-based Pregene enables rapid construct iteration and faster phase-one entry under China's more flexible regulatory environment for regenerative therapies.
• •Research-to-Manufacturing Lock-Down Tension: The critical scaling decision in cell therapy is determining when to freeze a construct's design for manufacturing scale-up versus continuing research iteration. Kite manages this through structured tension between process development and research teams. Companies should establish explicit lock-down criteria before entering late-stage development to avoid manufacturing delays driven by incremental construct modifications.